Low serum levels of CCL2 are associated with worse prognosis in patients with Acute Coronary Syndrome: 2-year survival analysis

Autor(es)

Lacerda Leocadio, Paola Caroline ^[1] ; dos Reis Menta, Penelope Lacrisio ^[1] ; Silva Dias, Melissa Tainan ^[1] ; Fraga, Julia Rodrigues ^[1] ; Goulart, Alessandra Carvalho ^[2] ; Santos, Itamar Souza ^{[3, 2]} ; Lotufo, Paulo Andrade ^{[3, 2]} ; Bensenor, Isabela Martins ^{[3, 2]} ; Alvarez-Leite, Jacqueline Isaura ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG - Brazil

^[2] Univ Sao Paulo, Hosp Univ, Ctr Pesquisa Clin & Epidemiol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Dept Clin Med, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BIOMEDICINE & PHARMACOTHERAPY; v. 109, p. 1411-1416, JAN 2019.
• Citações Web of Science: 0

Resumo

Inflammation is very important in Acute Coronary Syndrome (ACS) as well as in cardiac remodeling after an acute myocardial infarction (MI). Our study examined the prognostic value of Chemokine (C-C motif) ligand 2 (CCL2) in patients with ACS in the ERICO (Strategy of Registry of Acute Coronary Syndrome) study. We evaluated serum samples from 803 patients. The prognostic value of CCL2 was evaluated at the 2-year follow-up, according to cutoff points established by the median. Kaplan-Meier curves and Cox regression were used for analysis of all-cause mortality, cardiovascular mortality, and a combined outcome of fatal myocardial infarction or new non-fatal MI. There were 115 deaths from all causes, 78 deaths due to cardiovascular causes and 67 events in combined outcomes. CCL2 levels below the median (<= 100.9 pg/mL) were associated with increased risk of MI death or new non-fatal MI, even after model adjustment. Low serum levels of CCL2 shows a significant association with fatal or new non-fatal MI. (AU)

• Processo FAPESP: 12/14804-1 - Avaliação dos fatores prognósticos associados à síndrome coronariana aguda no momento da admissão hospitalar e após 30 dias do evento no estudo "Estratégia de registro de insuficiência coronariana" (ERICO)
• Beneficiário: Isabela Judith Martins Bensenor
• Modalidade de apoio: Auxílio à Pesquisa - Regular